@article {HATZICHRISTODOULOU5093, author = {GEORGIOS HATZICHRISTODOULOU and HUBERT K{\"U}BLER and HARTWIG SCHWAIBOLD and STEFAN WAGENPFEIL and CORNELIA EIBAUER and CHRISTIAN HOFER and J{\"U}RGEN GSCHWEND and UWE TREIBER}, title = {Nuclear Matrix Protein 22 for Bladder Cancer Detection: Comparative Analysis of the BladderChek{\textregistered} and ELISA}, volume = {32}, number = {11}, pages = {5093--5097}, year = {2012}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To compare nuclear matrix protein 22 expression by BladderChek{\textregistered} and ELISA, as urine-based assays for bladder cancer (BC) detection. Patients and Methods: Urine samples of 100 BC patients and 100 controls were analyzed. Comparative statistical evaluations were based on sensitivity and specificity. Results: Seventy-one patients had primary and 29 recurrent BC. The sensitivity of BladderChek{\textregistered} was significantly higher compared to ELISA in the overall cancer cohort and in patients with primary BC (p\<0.0001 and p=0.0001, respectively). Both tests demonstrated significant correlation of sensitivities and tumor stage/grade for the overall cancer cohort and for patients with primary BC. Both tests had specificity values of 100\% in healthy individuals. Specificity was 93\% for BladderChek{\textregistered} and 99\% for ELISA in patients with benign diseases (p=0.048). Conclusion: BladderChek{\textregistered} may be clinically more useful for BC detection. Due to high specificity, BladderChek{\textregistered} could be used for high-risk screening. However, due to its low sensitivity, BladderChek{\textregistered} cannot replace but only complement cystoscopy for BC detection.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/32/11/5093}, eprint = {https://ar.iiarjournals.org/content/32/11/5093.full.pdf}, journal = {Anticancer Research} }